GSK walks away from Alector pact as immuno-neurology bet fizzles
PartnershipnegativeNegative
AI Analysis
Summary
GSK terminated its partnership with Alector worth $700 million upfront following two high-profile trial failures in neurodegenerative disease treatments over the past year.
Outcome Details
GSK terminated partnership deal with Alector following two trial failures
Importance:8/10
Sentiment:
-0.90
partnership terminationtrial failureneurodegenerative diseaseimmuno-oncology
Read the original article
Published by Endpoints News on July 9, 2026 10:51 AM